ARTIMPLANT AB's INTERIM REPORT JANUARY 1 - SEPTEMBER 30, 2004
ARTIMPLANT AB's INTERIM REPORT JANUARY 1 - SEPTEMBER 30, 2004 IMPORTANT FDA-CLEARANCE. NORDIC REGION SALES HAVE COMMENCED ·Artimplant´s net sales for the 9 month period reached SEK 1.1 million (SEK 1.2 million) ·Losses after tax amounted to SEK -22.4 million (SEK -21.0 million) ·The result per share amounted to SEK -0.59 (SEK -0.97) ·FDA-clearance through a 510(k) for Artelon® CMC-I Spacer DEVELOPMENTS AFTER THE END OF THE PERIOD ·Development cooperation between Artimplant and Mölnlycke Health Care terminated Forthcoming financial reports: Release of year end results: February, 17, 2005